Tianjin Tianyao Pharmaceuticals Co Ltd
SSE:600488
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (24.2), the stock would be worth ¥0.63 (89% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 220 | ¥5.7 |
0%
|
| 3-Year Average | 24.2 | ¥0.63 |
-89%
|
| 5-Year Average | 24.6 | ¥0.64 |
-89%
|
| Industry Average | 35.7 | ¥0.93 |
-84%
|
| Country Average | 26.4 | ¥0.68 |
-88%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
T
|
Tianjin Tianyao Pharmaceuticals Co Ltd
SSE:600488
|
6.2B CNY | 220 | 381.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 13.7 |
| Median | 26.4 |
| 70th Percentile | 52.8 |
| Max | 2 279 450.9 |
Other Multiples
Tianjin Tianyao Pharmaceuticals Co Ltd
Glance View
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, development, production, and sales of corticosteroids and amino acid raw materials and preparations. The company is headquartered in Tianjin, Tianjin and currently employs 2,635 full-time employees. The company went IPO on 2001-06-18. The firm's primary products include corticosteroid bulk pharmaceutical chemicals (BPCs), amino acid BPCs and intermediate, such as dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinolone acetate, prednisone acetate, triamcinolone acetonide, propranolol propionate and betamethasone, among others. The firm mainly distributes its products in domestic and overseas markets.
